Bremelanotide
Also known as: Vyleesi, PT-141
Classification
Peptide
Regulatory Status
FDA-approved prescription product or labeled drug class
Overview
Bremelanotide is represented by its commonly described melanocortin receptor agonist mechanism. This conservative launch record supports search and overlap detection, not medical recommendation.
Evidence and limitations
Human/preclinical evidence breakdown is not available in this record.
Pathways
Benefits
Evidence reviewed for hypoactive sexual desire disorder per product label; BioStack presents this as educational reference, not a recommendation.
Interactions & cautions
Drug interactions
naltrexone — Potential additive or opposing effects may occur. (review)
These are observational flags for review, not individualized instructions.
Sources
Educational reference only — not medical advice.